Cash flows from operating activities: | |
Net loss | -36.05M |
Adjustments to reconcile net loss to net cash used in operating activities: | |
Depreciation | |
Common shares contribution to 401(k) | |
Share-based compensation expense | 6.2M |
Accrued interest on interest bearing obligations | |
Revaluation of warrant liabilities | |
Warrant modification expense | |
Amortization of discount on long-term debt | 1.08M |
Unrealized loss on foreign currency exchange | 384K |
Unrealized gain on foreign exchange options | |
Other non-cash adjustments | 79K |
Changes in assets and liabilities affecting cash: | |
Receivables | 3.31M |
Prepaid expenses and other assets | 676K |
Accounts payable and accrued liabilities | -4.54M |
Deferred revenue | -2.31M |
Other liabilities | -500K |
Net cash used in operating activities | |
Cash flows from investing activities: | |
Net purchase of property and equipment | -31K |
Net cash used in investing activities | |
Proceeds from issuance of long-term debt | 0 |
Proceeds from issuance of common shares | 45K |
Payment for modification of warrants | |
Net cash provided by financing activities | |
Effect of exchange rate changes on cash | |
Net increase in cash and cash equivalents | -45.15M |
Cash and cash equivalents at the beginning of the period | 65.77M |
Cash and cash equivalents at the end of the period | 20.62M |
Cash paid during the half of 2011 for: | |
Income taxes | |
Non-cash investing and financing activities: | |
Discount on long-term debt | |
Issuance and extinguishment of warrant liabilities | |
Interest added to principal balance on Novartis note |